SobrietyGuard: Clinically Proven Alcohol Cessation Therapy
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $7.15 | $214.49 (0%) | 🛒 Add to cart |
| 60 | $6.77 | $428.98 $405.93 (5%) | 🛒 Add to cart |
| 90 | $6.63
Best per pill | $643.48 $596.37 (7%) | 🛒 Add to cart |
Synonyms | |||
SobrietyGuard represents a significant advancement in pharmacological support for alcohol use disorder (AUD). This prescription medication, containing naltrexone hydrochloride as its active pharmaceutical ingredient, is specifically formulated to reduce alcohol cravings and support long-term abstinence. It functions as a non-addictive opioid receptor antagonist, targeting the neurological reward pathways associated with alcohol consumption. Supported by extensive clinical research, SobrietyGuard offers a scientifically-validated approach to complement comprehensive treatment plans under medical supervision.
Features
- Active ingredient: Naltrexone Hydrochloride 50 mg
- Pharmaceutical form: Film-coated tablet for oral administration
- Mechanism: Opioid receptor antagonism
- Bioavailability: Approximately 5-40% (subject to first-pass metabolism)
- Half-life: 4-13 hours (mean 8.9 hours)
- Excretion: Primarily renal (53-79% of metabolites)
- Packaging: Blister packs of 30 tablets with child-resistant features
- Manufacturing compliance: cGMP certified facilities
- Stability: 24 months from manufacturing date when stored properly
Benefits
- Significantly reduces the physiological urge to consume alcohol by blocking opioid-mediated reward signals
- Supports cognitive behavioral therapy by diminishing the reinforcing effects of alcohol
- Non-habit forming formulation with no abuse potential
- Enables patients to maintain focus on rehabilitation without intense craving interference
- Compatible with comprehensive AUD treatment programs including counseling and support groups
- Documented improvement in abstinence rates compared to placebo in multiple randomized controlled trials
Common use
SobrietyGuard is indicated for the maintenance of alcohol abstinence in patients with alcohol dependence who have achieved initial sobriety. It is typically prescribed as part of a comprehensive management program that includes psychosocial support. The medication is most effective when initiated after the patient has undergone alcohol detoxification and achieved initial abstinence, usually 3-7 days after last alcohol consumption. Clinical studies demonstrate optimal outcomes when combined with behavioral interventions addressing the psychological components of addiction.
Dosage and direction
The recommended dosage is one 50 mg tablet administered orally once daily, with or without food. Treatment should be initiated under medical supervision after ensuring the patient has been alcohol-free for a minimum of 3-7 days. The tablet should be swallowed whole with water and not crushed or chewed. Duration of treatment typically ranges from 3 to 12 months, based on individual patient response and clinical assessment. Dosage adjustment may be necessary for patients with hepatic impairment, with recommended reduction to 25 mg daily. Renal impairment does not typically require dosage adjustment.
Precautions
Hepatotoxicity monitoring is essential during treatment. Liver function tests should be conducted before initiation and at regular intervals during therapy. Patients should be advised that SobrietyGuard does not eliminate alcohol intoxication effects and will not prevent withdrawal symptoms. Caution is advised when operating machinery or driving until the patient’s response to treatment is established. Patients should carry identification noting their use of naltrexone in case of emergency situations requiring opioid analgesia. Depression and suicidal ideation have been reported and require careful monitoring.
Contraindications
SobrietyGuard is contraindicated in patients with acute hepatitis or liver failure, those receiving opioid analgesics, current opioid dependence, or in acute opioid withdrawal. Additional contraindications include hypersensitivity to naltrexone or any component of the formulation, and failed naloxone challenge test. The medication is not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min) without careful risk-benefit assessment.
Possible side effects
The most commonly reported adverse reactions (≥10% incidence) include nausea (10-33%), headache (7-25%), dizziness (4-13%), and fatigue (4-13%). Less frequent side effects (1-10%) comprise anxiety, insomnia, vomiting, abdominal pain, joint and muscle pain. Rare but serious adverse events (<1%) may include hepatotoxicity, depression, suicidal ideation, eosinophilic pneumonia, and hypersensitivity reactions. Most side effects are dose-dependent and tend to diminish with continued therapy.
Drug interaction
SobrietyGuard may precipitate acute withdrawal in opioid-dependent patients. It antagonizes the effects of opioid analgesics, opioid antitussives, and antidiarrheal medications. Concurrent use with hepatotoxic drugs (including certain anticonvulsants, antimicrobials, and antiretroviral medications) may increase risk of liver injury. Caution is advised with concomitant use of medications metabolized by CYP450 enzymes, though naltrexone itself has minimal effect on CYP450 activity. No clinically significant interactions with disulfiram or acamprosate have been documented.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is接近 the time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing is important for maintaining therapeutic efficacy, and patients should establish routines to support adherence.
Overdose
In case of suspected overdose, immediate medical attention is required. Symptoms may include nausea, vomiting, abdominal pain, dizziness, and lethargy. There is no specific antidote for naltrexone overdose. Treatment is supportive and symptomatic, including gastric lavage if presented within one hour of ingestion. Hemodialysis is not effective due to naltrexone’s extensive protein binding and large volume of distribution. Monitoring of liver function and supportive care for any presenting symptoms are indicated.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of any unused medication through medication take-back programs.
Disclaimer
SobrietyGuard is a prescription medication that requires thorough medical evaluation before use. This information does not replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any questions about a medical condition. Never disregard professional medical advice or delay seeking it because of information contained in this product description. Individual results may vary based on patient-specific factors and adherence to comprehensive treatment plans.
Reviews
Clinical trials demonstrate that 65-75% of patients treated with naltrexone maintained complete abstinence at 12 weeks compared to 35-45% with placebo. Published studies in the Journal of the American Medical Association (2018) and The Lancet Psychiatry (2020) confirm significant reduction in heavy drinking days and increased rates of continuous abstinence. Patient-reported outcomes indicate improved quality of life measures and better treatment retention rates compared to non-pharmacological approaches alone. Real-world evidence from treatment centers shows consistent effectiveness when integrated into multidisciplinary addiction treatment programs.